Genetic markers of abdominal obesity and weight loss after gastric bypass surgery

Aasbrenn, Martin; Svendstrup, Mathilde; Schnurr, Theresia M.; Hansen, Dorte Lindqvist; Worm, Dorte; Balslev-Harder, Marie; Grarup, Niels; Burgdorf, Kristoffer Sølvsten; Vestergaard, Henrik; Pedersen, Oluf; Angquist, Lars; Fenger, Mogens; Sørensen, Thorkild I. A.; Madsbad, Sten; Hansen, Torben

Published in:
PLoS ONE

DOI:
10.1371/journal.pone.0252525

Publication date:
2021

Document version
Publisher's PDF, also known as Version of record

Document license:
CC BY

Citation for published version (APA):
Aasbrenn, M., Svendstrup, M., Schnurr, T. M., Hansen, D. L., Worm, D., Balslev-Harder, M., Grarup, N., Burgdorf, K. S., Vestergaard, H., Pedersen, O., Angquist, L., Fenger, M., Sørensen, T. I. A., Madsbad, S., & Hansen, T. (2021). Genetic markers of abdominal obesity and weight loss after gastric bypass surgery. PLoS ONE, 16(5), [0252525]. https://doi.org/10.1371/journal.pone.0252525
RESEARCH ARTICLE

Genetic markers of abdominal obesity and weight loss after gastric bypass surgery

Martin Aasbrenn1,2*, Mathilde Svendstrup1,3,4*, Theresia M. Schnurr1, Dorte Lindqvist Hansen4, Dorte Worm5, Marie Balslev-Harder1, Niels Grarup1, Kristoffer Salvesten Burgdorf6, Henrik Vestergaard1,7, Oluf Pedersen5, Lars Ångquist1, Mogens Fenger8, Thorkild I. A. Sørensen1,9, Sten Madsbad10, Torben Hansen1

1 Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark, 2 Geriatric Research Unit, Department of Geriatrics, Bispebjerg-Frederiksberg University Hospital, Copenhagen, Denmark, 3 Department of Endocrinology, Bispebjerg-Frederiksberg University Hospital, Copenhagen, Denmark, 4 Steno Diabetes Center Copenhagen, Gentofte, Denmark, 5 Department of Medicine, Amager Hospital, Copenhagen, Denmark, 6 Department of Clinical Immunology, Copenhagen University Hospital, Copenhagen, Denmark, 7 Bornholms Hospital, Rønne, Denmark, 8 Department of Clinical Biochemistry, Hvidovre University Hospital, Copenhagen, Denmark, 9 Department of Public Health, University of Copenhagen, Copenhagen, Denmark, 10 Department of Endocrinology, Hvidovre University Hospital, Copenhagen, Denmark

* These authors contributed equally to this work.

Current address: Department of Endocrinology, Copenhagen University Hospital, Copenhagen, Denmark

Martin.Aasbrenn@gmail.com

Abstract

Background

Weight loss after bariatric surgery varies widely between individuals, partly due to genetic differences. In addition, genetic determinants of abdominal obesity have been shown to attenuate weight loss after dietary intervention with special attention paid to the rs1358980-T risk allele in the VEGFA locus. Here we aimed to test if updated genetic risk scores (GRSs) for adiposity measures and the rs1358980-T risk allele are linked with weight loss following gastric bypass surgery.

Methods

Five hundred seventy six patients with morbid obesity underwent Roux-en-Y gastric bypass. A GRS for BMI and a GRS for waist-hip-ratio adjusted for BMI (proxy for abdominal obesity), respectively, were constructed. All patients were genotyped for the rs1358980-T risk allele. Associations between the genetic determinants and weight loss after bariatric surgery were evaluated.

Results

The GRS for BMI was not associated with weight loss (β = -2.0 kg/100 risk alleles, 95% CI -7.5 to 3.3, p = 0.45). Even though the GRS for abdominal obesity was associated with an attenuated weight loss response adjusted for age, sex and center (β = -14.6 kg/100 risk alleles, 95% CI -25.4 to -3.8, p = 0.008), it was not significantly associated with weight loss after adjustment for baseline BMI (β = -7.9 kg/100 risk alleles, 95% CI -17.5 to 1.6, p = 0.11).
Similarly, the rs1358980-T risk allele was not significantly associated with weight loss (β = -0.8 kg/risk allele, 95% CI -2.2 to 0.6, p = 0.25).

Discussion
GRSs for adiposity derived from large meta-analyses and the rs1358980-T risk allele in the VEGFA locus did not predict weight loss after gastric bypass surgery. The association between a GRS for abdominal obesity and the response to bariatric surgery may be dependent on the association between the GRS and baseline BMI.

Introduction
Bariatric surgery is the most effective treatment for morbid obesity [1]. However, the weight loss response after bariatric surgery varies widely between individuals [2]. A part of this variation is probably due to genetic factors, as close biological relatives tend to have quite similar responses to weight loss interventions [3–5]. Potential specific genetic determinants of the individual variation in weight loss after bariatric surgery have been explored in some studies [5–13] with limited success.

Whether known adiposity-related risk single nucleotide polymorphisms (SNPs) are related to the response to weight loss interventions has been studied in recent years [10, 11, 14]. Genetic risk scores (GRSs) related to body mass index (BMI) based on 33 and 77 SNPs were not associated with the response to bariatric surgery in studies undertaken from 2014 and 2019 [11, 14]. In meta-analysis of GWASs from 2018 for BMI outcome in population studies, a total of 941 SNPs were identified [15]. Whether a GRS constructed from these 941 SNPs associates with the response to weight loss after bariatric surgery has not been investigated.

We previously replicated the association of a GRS based on 3 SNPs for abdominal obesity (waist-hip-ratio adjusted for BMI; WHR_BMI) with increased weight loss response after bariatric surgery [6, 11]. Conversely, in another study including an updated GRS of 49 SNPs associated with WHR_BMI, the genetic determinants were linked with attenuated weight loss after dietary intervention in women with special attention paid to the rs1358980-T risk allele [16]. The rs1358980-T risk allele is located upstream to a well-known angiogenesis gene; VEGFA, that codes for the vascular endothelial growth factor A (VEGF-A). The total number of SNPs known to be related to abdominal obesity has also increased rapidly. Thus in a recent meta-analysis, 346 loci were identified for the specific phenotype WHR_BMI [17]. An updated GRS based on these 346 SNPs has not been investigated in relation to the response to weight loss after bariatric surgery.

The primary aim of this study was to examine the effect of recently developed GRSs for BMI and WHR_BMI, respectively, on the inter-individual variations in weight loss after bariatric surgery. The secondary aim was to similarly examine the association of rs1358980-T risk allele in the VEGFA locus with weight loss after bariatric surgery.

Materials and methods
Study design and setting
Danish adult patients ≥ 25 years of age with morbid obesity (BMI > 50 kg/m² or BMI > 35 kg/m² with obesity-related complications) being offered bariatric surgery were included. Possible obesity-related complications included hypertension, diabetes mellitus, sleep apnea,
respiratory failure or osteoarthrosis of weight-bearing joints. All the included patients were operated with Roux-en-Y gastric bypass surgery, created with a 25 ml gastric pouch, a 75 cm long bilo-pancreatic limb and a Roux limb of 100 cm [18].

From June 2009 to April 2013, patients with morbid obesity previously referred to a public obesity center at Hvidovre Hospital, Capital Region of Denmark, were invited to participate. Information was collected at visits to the hospital before, 1 year after (mean 392 days after the surgery, standard deviation (SD) 59 days) and 2 years after Roux-en-Y gastric bypass surgery (mean 776 days after the surgery, SD 71 days). Between December 2007 and November 2009, adult patients referred to the Hamlet Hospital, Søborg, Capital Region of Denmark, were invited to participate. The patients operated at Hamlet Hospital were evaluated at Steno Diabetes hospital 1 year after surgery (mean 371 days after the surgery, SD 26 days) and at a second control 2–4 years after Roux-en-Y gastric bypass surgery (mean 838 days after the surgery, SD 319 days, interquartile range 531 days). In total, 1511 patients agreed to participate. All study visits included blood sampling and measurement of body weight and height.

Variables

**Genotyping.** DNA was extracted from blood leukocytes at LGC Genomics (LGC, Middlesex, United Kingdom), and 1511 samples from all the participants at inclusion (n = 1414) were genotyped by the Illumina HumanCoreExome Beadchip (Illumina, San Diego, CA) using Illumina’s HiScan system at the Novo Nordisk Foundation Center for Basic Metabolic Research in Copenhagen, Denmark. Genotypes were called using the Genotyping module (version 1.9.4) of GenomeStudio software (version 2011.1, Illumina). During quality control, we excluded samples that were first degree relatives (n = 34), ethnic outliers (n = 72), had extreme inbreeding coefficients (n = 99), mislabeled gender (n = 8) or a call rate < 95% (n = 177), leaving 1024 individuals. Among these genotyped individuals, patients who did not undergo bariatric surgery or did not have the required follow-up visits were excluded, leaving 576 individuals in the main analysis; 351 recruited at Hvidovre Hospital and 225 recruited at Hamlet Hospital. SNPs that were used for the calculation of the GRSs were either directly genotyped or imputed to the Haplotype Reference Consortium panel (HRC, version 1.1). The imputation quality was high (INFO > 0.95) for all imputed variants included in the GRS constructions. No included variants were significantly deviating from Hardy-Weinberg equilibrium (p > 0.05).

**GRS construction.** We constructed weighted GRSs by summing the number of risk-increasing alleles weighted by the effect size of the variant estimated in the GWAS discovery studies [15, 17]. We then normalized the weighted GRS to make effect sizes of the weighted GRSs comparable to risk allele effects [19]. The GRS-BMI_{941} for BMI was based on 941 SNPs associated with cross-sectional BMI in European populations [15]. The GRS-WHR_{344} was based on 344 (out of 346) SNPs that were associated with WHR_{BMI} in the discovery meta-analysis [17]. We only included 344 (out of the 346 SNPs) because two SNPs (rs805768 and rs7798002) were non-biallelic and therefore excluded from the GRS calculation.

Anthropometrics

Body weight was measured at the first visit to the obesity center (initial body weight) and at the clinical controls after bariatric surgery [19]. The lowest body weight at a post-surgical clinical visit was used as nadir body weight in the analyses. BMI (kg/m^2) was calculated as the body weight (kg) divided by the height (m) squared [20]. WHR was measured at the first visit to the obesity center in a subset of 272 patients. Waist circumference was measured in cm at the anatomical location with the largest circumference, hip circumference was measured at the largest circumference around the buttocks and waist-hip-ratio (WHR) was calculated as [waist
circumference] / [hip circumference]. Weight loss was calculated as [initial weight]–[nadir weight].

Statistical analysis
Baseline data are presented as SDs or proportions (percentages).

The associations between the three genetic determinants (GRS-BMI_{941}, GRS-WHR_{344}, VEGFA-rs1358980-T) and baseline BMI and WHR, respectively, were examined with linear regression (WHR was adjusted for baseline BMI to derive WHR_{BMI}). The associations between weight loss after bariatric surgery and BMI and WHR_{BMI} were also examined with linear regression.

To answer the primary aim, the GRS-BMI_{941} and the GRS-WHR_{344} were used as explanatory variables in multiple linear regression analyses with weight loss as dependent variable. To answer the secondary aim, VEGFA-rs1358980-T was used in the same fashion. These analyses are presented adjusted for baseline age, sex and recruitment center and in subsequent analyses additionally adjusted for baseline BMI. Analyses are also presented stratified by sex. Additional adjustment for follow-up-time and BMI criteria used (above 50 kg/m^2 or above 35 kg/m^2 with obesity-related complications) was performed, but excluded from the final presentation as it did not substantially change the main results.

P-values below 0.05 were considered as statistically significant. Data was analyzed with SPSS version 25 for Windows (Armonk, NY).

Ethics
The study was conducted in accordance with the Declaration of Helsinki and was approved by the Scientific Ethics Committee of the Capital Region, Denmark, protocol number HD2009-78. Informed consent was obtained from all individual participants included in the study.

Results
A total of 576 patients (74% females) with a mean age of 45.4 ± SD 10.3 years and a mean BMI of 44.3 ± 5.2 kg/m^2 were included. The mean change in BMI from inclusion to the nadir 1–3 years after bariatric surgery was 14.4 kg/m^2, corresponding to an average weight loss of 42 kg (Table 1).

There was a direct association between baseline BMI and weight loss in kg (β = 1.22 kg/[kg/m^2], 95% CI 1.03 to 1.41, p < 0.001). In the subset of 272 patients with measured baseline WHR, the mean WHR was 0.95 ± 0.11. We observed an inverse association between baseline WHR_{BMI} and weight loss in kg (β = -11.8 kg/unit, 95% CI -23.3 to -0.3, p = 0.047) driven by a particularly strong effect in women (S1 Table).

The genetic determinants examined in the study are given in Table 2.

Mean GRS-BMI_{941} was 913 ± 17 risk alleles, and mean GRS-WHR_{344} was 342 ± 10 risk alleles (Table 1). The GRS-BMI_{941} was not significantly associated with BMI or WHR_{BMI} at baseline. The GRS-WHR_{344} was inversely associated with baseline BMI (β = -5.5 kg/m^2/100 risk alleles, 95% CI -9.7 to -1.2, p = 0.01) and positively associated with WHR_{BMI} (β = 0.15 units/100 risk alleles, 95% CI 0.01 to 0.29, p = 0.04). VEGFA-rs1358980-T was not associated with BMI or WHR_{BMI} at baseline (Table 3).

The GRS-BMI_{941} was not significantly associated with the weight loss response to bariatric surgery in the cohort as a whole (β = -1.3 kg/100 risk alleles, 95% CI -7.5 to 4.9, p = 0.68). A high GRS-WHR_{344} was associated with an attenuated weight loss before adjustment for baseline BMI (β = -14.6 kg/100 risk alleles, 95% CI -25.4 to -3.8, p = 0.008), but not after adjustment for baseline BMI (β = -7.9 kg/100 risk alleles, 95% CI -17.5 to 1.6, p = 0.11). The
VEGFA-rs1358980-T risk allele was not significantly associated with weight loss (β = -1.4 kg/risk allele, 95% CI -2.9 to 0.1, p = 0.07) (Table 4).

Discussion

Neither was the GRS-BMI\textsubscript{941} associated with the weight loss response after bariatric surgery in the total cohort nor was the GRS-WHR\textsubscript{344} associated with an attenuated weight loss response to bariatric surgery after adjustment for baseline BMI. Similarly, we did not find a significant association between the VEGFA-rs1358980-T risk allele and the weight loss response with or without adjustment for baseline BMI in the total cohort.

The GRS-BMI\textsubscript{941} was not associated with baseline BMI in our cohort, neither in the total cohort nor in men or women separately. This could be due to a truncation effect, as patients in bariatric surgery cohorts are included based on whether BMI is above a specific threshold. Additionally, as the SNPs used in the GRS-BMI\textsubscript{941} are based on the BMI distribution in the general population, the association between this GRS and BMI might not be present among patients in in the extreme upper end of the BMI distribution. In line with previous studies using GRSSs based on fewer SNPs [11, 14] we also failed to show any links between the GRS-BMI\textsubscript{941} and weight loss response following bariatric surgery.

Table 1. Demographics, clinical characteristics, and genetic determinants in the cohort, stratified by sex.

|                        | Whole group | Female | Male |
|------------------------|-------------|--------|------|
| Included patients, n   | 576         | 428 (74%) | 148 (26%) |
| Center, n              |             |        |      |
| Hvidovre               | 351 (61%)   | 250 (71%) | 101 (29%) |
| Hamlet                 | 225 (39%)   | 179 (79%) | 47 (21%) |
| Age (years)            | 45.4 (10.3) | 45.0 (10.3) | 46.4 (10.3) |
| Height (cm)            | 170.6 (9.4) | 166.8 (6.6) | 181.5 (7.7) |
| Waist circumference (cm)| 127.9 (14.4) | 123.0 (12.3) | 140.2 (11.5) |
| Hip circumference (cm) | 134.9 (13.1) | 136.6 (13.0) | 130.6 (12.5) |
| Waist-hip-ratio        | 0.95 (0.11) | 0.90 (0.08) | 1.08 (0.08) |
| Initial weight (kg)    | 129.5 (21.2) | 123.2 (17.3) | 147.8 (20.6) |
| Nadir weight (kg)      | 87.5 (18.3)  | 81.8 (14.8)  | 103.9 (17.8) |
| Change in weight (kg)  | 42.0 (13.3)  | 41.3 (12.6)  | 43.9 (15.1)  |
| Weight loss (%)        | 32.4 (8.5)   | 33.4 (8.3)   | 29.5 (8.5)   |
| Initial BMI (kg/m²)    | 44.3 (5.2)   | 44.2 (5.1)   | 44.9 (5.5)   |
| Nadir BMI (kg/m²)      | 29.9 (4.9)   | 29.4 (4.8)   | 31.5 (4.9)   |
| BMI loss (kg/m²)       | 14.4 (4.4)   | 14.8 (4.3)   | 13.3 (4.5)   |
| GRS-BMI\textsubscript{941} * | 913 (17) | 912 (17) | 914 (17) |
| GRS-WHR\textsubscript{344} * | 342 (10) | 342 (10) | 340 (10) |
| VEGFA-rs1358980       |             |        |      |
| 0 risk alleles         | 167 (29%)   | 123 (29%) | 44 (30%) |
| 1 risk allele          | 283 (49%)   | 216 (50%) | 67 (45%) |
| 2 risk alleles         | 126 (22%)   | 90 (21%)  | 37 (25%) |

Data from 576 patients are included in all rows, except waist circumference, hip circumference and waist-hip-ratio where 272 patients are included. BMI; Body mass index. GRS; Genetic risk score. WHR; Waist-hip-ratio. * weighted sum of risk alleles.

Presented as means with standard deviations within parentheses; alternatively as numbers with percentages within parentheses.

https://doi.org/10.1371/journal.pone.0252525.t001

VEGFA-rs1358980-T risk allele was not significantly associated with weight loss (β = -1.4 kg/risk allele, 95% CI -2.9 to 0.1, p = 0.07) (Table 4).
The GRS-WHR\textsubscript{344} was as expected positively associated with WHR\textsuperscript{BMI} at baseline in the total cohort as well as when both sexes were analyzed separately [17]. However, the GRS-WHR\textsubscript{344} was further (somewhat surprising) inversely associated with BMI at baseline. A possible explanation could be the genetic pathways linking some genetic markers of abdominal obesity with a relatively lower BMI as suggested by Lu et al [22]. The association pattern might also be related to the so-called ‘adipose expandability hypothesis’ suggesting abdominal obesity to be a result of a reduced ability to store fat subcutaneously, leading to visceral and ectopic fat storing further eliciting insulin resistance and other dys-metabolic traits [20]. In other words, a reduced capability of adipose tissue expansion leads to a more dys-metabolic abdominal obesity at a lower BMI threshold. Patients with abdominal obesity and metabolic disturbances (e.g. type 2 diabetes) will be accepted for bariatric surgery at a lower BMI due to the applied selection criteria for surgery in Denmark [23]. This practice might explain the inverse association between GRS-WHR\textsubscript{344} and BMI in the current cohort of patients accepted for bariatric surgery.

The GRS-WHR\textsubscript{344} was as expected positively associated with WHR\textsuperscript{BMI} at baseline in the total cohort as well as when both sexes were analyzed separately [17]. However, the GRS-WHR\textsubscript{344} was further (somewhat surprising) inversely associated with BMI at baseline. A possible explanation could be the genetic pathways linking some genetic markers of abdominal obesity with a relatively lower BMI as suggested by Lu et al [22]. The association pattern might also be related to the so-called ‘adipose expandability hypothesis’ suggesting abdominal obesity to be a result of a reduced ability to store fat subcutaneously, leading to visceral and ectopic fat storing further eliciting insulin resistance and other dys-metabolic traits [20]. In other words, a reduced capability of adipose tissue expansion leads to a more dys-metabolic abdominal obesity at a lower BMI threshold. Patients with abdominal obesity and metabolic disturbances (e.g. type 2 diabetes) will be accepted for bariatric surgery at a lower BMI due to the applied selection criteria for surgery in Denmark [23]. This practice might explain the inverse association between GRS-WHR\textsubscript{344} and BMI in the current cohort of patients accepted for bariatric surgery.

The association between GRS-WHR\textsubscript{344} and attenuated weight loss after bariatric surgery is supported by previous comparable findings in data of non-surgical weight loss from the NUGENOB study [16]. However, in contrast to the findings in the NUGENOB study, the significance of the association in the present study was lost after adjustment for baseline BMI.

Table 2. Genetic determinants examined in the manuscript.

| Genetic exposure | Description | Reference | Number of SNPs |
|------------------|-------------|-----------|---------------|
| GRS-BMI\textsubscript{941} | Genetic risk score for BMI based on meta-analysis | Yengo et al. 2018 [15] | 941 |
| GRS-WHR\textsubscript{344} | Genetic risk score for abdominal obesity based on meta-analysis of SNPs associated with WHR adjusted for BMI | Pulit et al. 2019 [17] | 344 |
| VEGFA-rs1358980 | SNP of special interest in the analysis of weight changes | Shungin et al. 2015 [21] Svendsrup et al. 2018 [16] | 1 |

BMI; Body mass index. WHR; Waist-hip-ratio. SNP; Single nucleotide polymorphism.

https://doi.org/10.1371/journal.pone.0252525.t002

Table 3. Associations between genetic determinants and anthropometric traits at baseline.

| Genetic exposure | Association with BMI at baseline\textsuperscript{1} | Association with WHR\textsuperscript{BMI} at baseline\textsuperscript{2} |
|------------------|----------------------|----------------------|
|                  | \(\beta\) | 95% CI | p | \(\beta\) | 95% CI | p |
| Whole group      |          |         |    |          |         |    |
| GRS-BMI\textsubscript{941} | 0.7 | -1.7 to 3.2 | 0.56 | 0.00 | -0.07 to 0.08 | 0.97 |
| GRS-WHR\textsubscript{344} | -5.5 | -9.7 to -1.2 | 0.01 | 0.15 | 0.01 to 0.29 | 0.04 |
| VEGFA-rs1358980 | -0.5 | -1.1 to 0.1 | 0.11 | 0.00 | -0.02 to 0.02 | 0.96 |
| Women alone      |          |         |    |          |         |    |
| GRS-BMI\textsubscript{941} | 0.5 | -2.3 to 3.3 | 0.73 | -0.04 | -0.10 to 0.03 | 0.26 |
| GRS-WHR\textsubscript{344} | -1.5 | -6.3 to 3.3 | 0.54 | 0.14 | 0.02 to 0.26 | 0.02 |
| VEGFA-rs1358980 | -0.3 | -1.0 to 0.4 | 0.44 | 0.01 | -0.01 to 0.03 | 0.31 |
| Men alone        |          |         |    |          |         |    |
| GRS-BMI\textsubscript{941} | 1.1 | -4.2 to 6.4 | 0.68 | -0.05 | -0.15 to 0.04 | 0.27 |
| GRS-WHR\textsubscript{344} | -16.3 | -25.1 to -7.4 | <0.001 | 0.24 | 0.06 to 0.41 | 0.01 |
| VEGFA-rs1358980 | -1.1 | -2.3 to 0.2 | 0.09 | -0.01 | -0.04 to 0.01 | 0.31 |

BMI; Body mass index. CI; Confidence interval. GRS; Genetic risk score. WHR; Waist-hip-ratio. WHR\textsuperscript{BMI}; Waist-hip-ratio adjusted for BMI.

Linear regression with respectively BMI (kg/m\(^2\); n = 576) and WHR adjusted for BMI (unit-free; n = 272) as dependent variable. The presented \(\beta\) values are effects per 100 risk alleles (GRS-BMI\textsubscript{941} and GRS-WHR\textsubscript{344}) or effects per risk allele (VEGFA-rs1358980).

https://doi.org/10.1371/journal.pone.0252525.t003
Reported studies of patients undergoing bariatric surgery have also pointed to relationships between weight loss and genetic markers associated with abdominal obesity. Notably, these studies used excess BMI loss as the weight loss phenotype, a variable that is strongly related to the baseline BMI [6, 11]. Our data indicate that the association between GRS-WHR and weight loss response to bariatric surgery might be explained by the association between the GRS-WHR and baseline anthropometrics, especially BMI [17, 21]. Baseline BMI is known to be associated with the response to weight loss interventions. The choice of weight loss phenotype is therefore of great importance in this type of study. For mathematical reasons, the excess body mass index and excess weight loss variables are inversely associated with baseline BMI in bariatric surgery cohorts, while BMI change or weight change are positively associated with baseline BMI [24].

The polymorphisms related to body fat distribution have been suggested to mechanistically act in adipose tissue in three main pathways: Adipogenesis, angiogenesis and non-specified transcriptional regulation [21]. Adipogenesis and angiogenesis are important for adipose tissue function and expansion and impairment of these mechanisms lead to metabolic disturbances through induction of hypoxia, inflammation and fibrosis in the tissue [25–29]. Human studies have further shown that fibrosis and reduced angiogenesis in adipose tissue may attenuate weight loss response after gastric bypass [30–32]. Therefore, it may be hypothesized that various genetic factors determinant for abdominal obesity and for weight loss responsiveness following surgical interventions may operate via common pathways of adipogenesis and angiogenesis.

We investigated the VEGFA-rs1358980-T risk allele as a potential candidate SNP for angiogenesis. Previously, we reported that the variant attenuated weight loss in women in a diet-induced weight loss program in the NUGENOB study [16]. The polymorphism is located at a genome position upstream to VEGFA, an angiogenesis gene encoding the VEGF-A protein. The protein induces angiogenesis and elevated plasma and adipose tissue concentrations of VEGF-A in obesity are known to decline following weight loss [32, 33]. In the present study the VEGFA-rs1358980-T risk allele was not significantly associated with BMI or WHR at

| Genetic exposure | Model 1 | Model 2 |
|------------------|---------|---------|
|                  | β       | 95% CI  | p     | β       | 95% CI  | p     |
| Whole group      |         |         |       |         |         |       |
| GRS-BMI<sub>941</sub> | -1.3   | -7.5 to 4.9 | 0.68 | -2.0   | -7.5 to 3.3 | 0.45 |
| GRS-WHR<sub>344</sub> | -14.6  | -25.4 to -3.8 | 0.008 | -7.9   | -17.5 to 1.6 | 0.11 |
| VEGFA-rs1358980  | -1.4   | -2.9 to 0.1  | 0.07 | -0.8   | -2.2 to 0.6  | 0.25 |
| Women alone      |         |         |       |         |         |       |
| GRS-BMI<sub>941</sub> | 2.4    | -4.4 to 9.1  | 0.49 | 1.8    | -4.1 to 7.7  | 0.54 |
| GRS-WHR<sub>344</sub> | -8.7   | -20.6 to 3.2  | 0.15 | -6.8   | -17.2 to 3.6  | 0.20 |
| VEGFA-rs1358980  | -0.5   | -2.2 to 1.2  | 0.56 | -0.18  | -1.7 to 1.3  | 0.81 |
| Men alone        |         |         |       |         |         |       |
| GRS-BMI<sub>941</sub> | -11.4  | -25.9 to 3.1  | 0.12 | -13.7  | -26.4 to -1.0 | 0.04 |
| GRS-WHR<sub>344</sub> | -30.8  | -55.2 to -6.3  | 0.01 | -10.1  | -33.1 to 12.9 | 0.39 |
| VEGFA-rs1358980  | -3.5   | -6.9 to -0.2  | 0.04 | -2.34  | -5.33 to 0.65 | 0.13 |

BMI; Body mass index. CI; Confidence interval. GRS; Genetic risk score. WHR; Waist-hip-ratio.

Linear regression with weight change as dependent variable (Δkg; n = 576). The presented β values are effects per 100 risk alleles (GRS-BMI<sub>941</sub> and GRS-WHR<sub>344</sub>) or per risk allele (VEGFA-rs1358980).

Model 1: adjustments for sex, age and inclusion center. Model 2: adjustments for sex, age, inclusion center and baseline BMI.

https://doi.org/10.1371/journal.pone.0252525.t004
baseline. The inverse effect direction of VEGFA-rs1358980-T on the weight loss response was consistent with the findings from the NUGENOB study [16]. However, we cannot exclude that lack of significance between VEGFA-rs1358980-T and baseline WHR\textsubscript{BMI} as well as with weight loss in the present study might be an issue of statistical power.

The application of GRSs to clinical trials is of no direct clinical relevance at the present due to very small effect sizes of GRS. Still, such studies are crucial for understanding potential genetic linkages between traits and thereby for fostering novel hypothesis for biological pathways behind shared phenotypes to be tested in subsequent mechanistic experiments. Angiogenesis may be one of the mechanisms that govern the individual variation in response to weight loss treatment by possibly affecting adipose tissue flexibility. The weight change after bariatric surgery might be associated with genetic factors associated with weight change rather than SNPs associated with absolute values of BMI and for instance the putative role of VEGFA should be explored further; one approach could be a meta-analysis of weight loss following interventions related to diet, physical activity, drugs or bariatric surgery [34].

Finally, it should be borne in mind that a multitude of factors influence weight loss after bariatric surgery, like procedure of surgery, postprandial gastrointestinal hormone responses, diabetes status, preoperative eating disturbances, postoperative eating pattern and adaptive changes of the intestinal microbiota [35–37]. The many factors makes it challenging to disentangle the different effects including the potential roles of the GRSs.

### Strengths and limitations

The main strength of this study is that the evaluated GRSs are established risk scores based on large population studies, rather than GRSs that have been constructed and tested in the same cohort. Other strengths include standardized surgery, genotyping of high quality and appropriate methods for imputation of genotypes. The cohort is larger than many of the comparable studies examining GRSs for weight loss following bariatric surgery, but smaller than genetic studies in general. An additional strength is that the patients are investigated 1–3 years after surgery, around the time point with highest weight loss.

WHR was only measured in half of the patients at baseline, which limits the exploration of the data due to reduced statistical power. Three different genetic markers were evaluated without correction for multiple testing; if applied, this would not in any substantial way affect the main interpretations given the general non-significance nature of the results. The measurement of hip and waist circumference might be slightly imprecise among the patients with highest BMI. While the loss to follow up is a third weakness that could lead to bias, this is not expected to mainly be caused by the genetics of the patients and should therefore not affect the main conclusions of the study.

### Conclusions

With an updated genome-wide GRS for BMI and with a genome-wide GRS for abdominal obesity we were unable to demonstrate any significant relationships between genetics and weight loss following bariatric surgery in morbidly obese patients. Similarly, the rs1358980-T risk allele in the VEGFA locus was not linked with an attenuated weight loss. Future developments of clinically relevant GRS for predicting weight loss after various interventions including bariatric surgery are dependent on progress in the identification of specific genome regions related to weight loss per se to complement current knowledge of the genetics behind various adiposity measures.
Supporting information

S1 Table. Associations between baseline anthropometrics and weight loss after bariatric surgery.

(DOCX)

Author Contributions

Conceptualization: Mathilde Svendstrup, Theresia M. Schnurr, Dorte Lindqvist Hansen, Dorte Worm, Niels Grarup, Henrik Vestergaard, Oluf Pedersen, Lars Ångquist, Thorkild I. A. Sørensen, Sten Madsbad, Torben Hansen.

Data curation: Martin Aasbrenn, Mathilde Svendstrup, Theresia M. Schnurr, Dorte Lindqvist Hansen, Dorte Worm, Marie Balslev-Harder, Niels Grarup, Kristoffer Sølvsten Burgdorf, Henrik Vestergaard.

Formal analysis: Martin Aasbrenn, Mathilde Svendstrup, Theresia M. Schnurr, Lars Ångquist, Sten Madsbad, Torben Hansen.

Funding acquisition: Sten Madsbad, Torben Hansen.

Investigation: Martin Aasbrenn, Mathilde Svendstrup, Theresia M. Schnurr, Dorte Lindqvist Hansen, Dorte Worm, Marie Balslev-Harder, Oluf Pedersen, Mogens Fenger, Thorkild I. A. Sørensen, Sten Madsbad, Torben Hansen.

Methodology: Mathilde Svendstrup, Theresia M. Schnurr, Niels Grarup, Kristoffer Sølvsten Burgdorf, Henrik Vestergaard, Lars Ångquist, Mogens Fenger, Thorkild I. A. Sørensen, Sten Madsbad, Torben Hansen.

Project administration: Martin Aasbrenn, Mathilde Svendstrup, Dorte Lindqvist Hansen, Dorte Worm, Marie Balslev-Harder, Niels Grarup, Kristoffer Sølvsten Burgdorf, Henrik Vestergaard, Sten Madsbad, Torben Hansen.

Supervision: Mathilde Svendstrup, Theresia M. Schnurr, Henrik Vestergaard, Oluf Pedersen, Lars Ångquist, Thorkild I. A. Sørensen, Sten Madsbad, Torben Hansen.

Validation: Mathilde Svendstrup, Torben Hansen.

Writing – original draft: Martin Aasbrenn, Mathilde Svendstrup, Theresia M. Schnurr, Dorte Lindqvist Hansen, Dorte Worm, Marie Balslev-Harder, Niels Grarup, Kristoffer Sølvsten Burgdorf, Henrik Vestergaard, Oluf Pedersen, Lars Ångquist, Mogens Fenger, Thorkild I. A. Sørensen, Sten Madsbad, Torben Hansen.

Writing – review & editing: Martin Aasbrenn, Mathilde Svendstrup, Theresia M. Schnurr, Dorte Lindqvist Hansen, Dorte Worm, Marie Balslev-Harder, Niels Grarup, Kristoffer Sølvsten Burgdorf, Henrik Vestergaard, Oluf Pedersen, Lars Ångquist, Mogens Fenger, Thorkild I. A. Sørensen, Sten Madsbad, Torben Hansen.

References

1. Colquitt JL, Pickett K, Loveman E, Frampton GK. Surgery for weight loss in adults. Cochrane Database Syst Rev. 2014(8):CD003641. https://doi.org/10.1002/14651858.CD003641.pub4 PMID: 25105982

2. Dirksen C, Jorgensen NB, Bojsen-Moller KN, Kielgast U, Jacobsen SH, Clausen TR, et al: Gut hormones, early dumping and resting energy expenditure in patients with good and poor weight loss response after Roux-en-Y gastric bypass. Int J Obes. 2013; 37: 1452–1459. https://doi.org/10.1038/ijo.2013.15 PMID: 23419600
3. Hainer V, Zamrazilova H, Spalova J, Hainerova I, Kunesova M, Aldhoon B, et al: Role of hereditary factors in weight loss and its maintenance. Physiol Res. 2008, 57 Suppl 1:S1–15. PMID: 18271696

4. Hainer V, Stunkard AJ, Kunesova M, Parizkova J, Stich V, Allison DB: Intrapair resemblance in very low calorie diet-induced weight loss in female obese identical twins. Int J Obes. 2000; 24: 1051–1057. https://doi.org/10.1038/sj.ijo.0801358 PMID: 10951545

5. Hatoum IJ, Greenawalt DM, Cotsapas C, Reitman ML, Daly MJ, Kaplan LM: Heritability of the weight loss response to gastric bypass surgery. J Clin Endocrinol Metab. 2011; 96: E1630–1633. https://doi.org/10.1210/jc.2011-1130 PMID: 21832118

6. Bandstein M, Voisin S, Nilsson EK, Schultes B, Ernst B, Thurnheer M et al: A Genetic Risk Score Is Associated with Weight Loss Following Roux-en-Y Gastric Bypass Surgery. Obes Surg. 2016; 26: 2183–2189. https://doi.org/10.1007/s11695-016-2072-9 PMID: 26833235

7. Rinella ES, Still C, Shao Y, Wood GC, Chu X, Salerno B et al: Genome-wide association of single-nucleotide polymorphisms with weight loss outcomes after Roux-en-Y gastric bypass surgery. J Clin Endocrinol Metab. 2013, 98: E131–136. https://doi.org/10.1210/jc.2012-3421 PMID: 23633212

8. Bandstein M, Mwinyi J, Ernst B, Thurnheer M, Schultes B, Schioth HB: A genetic variant in proximity to the gene LYPLAL1 is associated with lower hunger feelings and increased weight loss following Roux-en-Y gastric bypass surgery. Scand J Gastroenterol. 2016; 51: 1050–1055. https://doi.org/10.3109/00365521.2016.1166519 PMID: 27181159

9. Hatoum IJ, Greenawalt DM, Cotsapas C, Daly MJ, Reitman ML, Kaplan LM: Weight loss after gastric bypass is associated with a variant at 15q26.1. Am J Hum Genet. 2013; 92: 827–834. https://doi.org/10.1016/j.ajhg.2013.04.009 PMID: 23643386

10. de Toro-Martín J, Guenard F, Tchernof A, Perusse L, Marceau S, Vohl MC: Polygenic risk score for predicting weight loss after bariatric surgery. JCI insight 2018; 3: e122011. https://doi.org/10.1172/jci.insight.122011 PMID: 30185664

11. Aasbrenn M, Schnurr TM, Have CT, Svendstrup M, Hansen DL, Worm D et al: Genetic Determinants of Weight Loss After Bariatric Surgery. Obes surg. 2019; 29: 2554–2561. https://doi.org/10.1007/s11695-019-03878-5 PMID: 31001758

12. Katsareli EA, Amerikanou C, Rouskas K, Dimopoulos A, Diamantis T, Alexandrou A, et al: A Genetic Risk Score for the Estimation of Weight Loss After Bariatric Surgery. Obes Surg. 2020; 30: 1482–1490. https://doi.org/10.1007/s11695-019-04320-6 PMID: 31650404

13. Kakela P, Jaaskelainen T, Torpstrom J, Iives I, Venesmaa S, Paakonen M, et al: Genetic risk score does not predict the outcome of obesity surgery. Obes Surg. 2014; 24: 128–133. https://doi.org/10.1007/s11695-013-1080-2 PMID: 24065439

14. Yengo L, Sidorenko J, Kemper KE, Zheng Z, Wood AR, Weedon MN, et al: Meta-analysis of genome-wide association studies for height and body mass index in approximately 700 000 individuals of European ancestry. Hum Mol Genet. 2018; 27: 3641–3649. https://doi.org/10.1093/hmg/ddy271 PMID: 30124842

15. Svendstrup M, Allin KH, Sorensen TIA, Hansen TH, Grarup N, Hansen T, et al: Genetic risk scores for body fat distribution attenuate weight loss in women during dietary intervention. Int J Obes. 2018; 42: 372–375. https://doi.org/10.1038/ijo.2017.279 PMID: 29142243

16. Puhl SL, Stoneman C, Morris AP, Wood AR, Glastonbury CA, Tyrrell J, et al: Meta-analysis of genome-wide association studies for body fat distribution in 694 649 individuals of European ancestry. Hum Mol Genet 2019; 28: 166–174. https://doi.org/10.1093/hmg/ddy327 PMID: 30239722

17. Fenger M, Hansen DL, Worm D, Hvorsli L, Kristiansen VB, Carlsson ER, et al: Gastric bypass surgery reveals independency of obesity and diabetes mellitus type 2. BMC Endocr Disord. 2016; 16: 59. https://doi.org/10.1186/s12902-016-0140-8 PMID: 27829412

18. Lukacs Krogager M, Skals RK, Appel EVR, Schnurr TM, Engelbrechtsen L, Have CT, et al: Hypertension genetic risk score is associated with burden of coronary heart disease among patients referred for coronary angiography. PLoS One. 2018; 13:e0208645. https://doi.org/10.1371/journal.pone.0208645 PMID: 30566436

19. Virtue S, Vidal-Puig A: Adipose tissue expandability, lipotoxicity and the Metabolic Syndrome—an allostatic perspective. Biochimica et biophysica acta. 2010; 1801: 338–348. https://doi.org/10.1016/j.bbalip.2009.12.006 PMID: 20056169

20. Shungin D, Winkler TW, Croteau-Chonka DC, Ferreira T, Locke AE, Magi R, et al: New genetic loci link adipose and insulin biology to body fat distribution. Nature. 2015; 518: 187–196. https://doi.org/10.1038/nature14132 PMID: 26673412
22. Lu Y, Day FR, Gustafsson S, Buchkovich ML, Na J, Bataille V, et al: New loci for body fat percentage reveal link between adiposity and cardiometabolic disease risk. Nat Commun. 2016; 7: 10495. https://doi.org/10.1038/ncomms10495 PMID: 26833246

23. Borisenko O, Colpan Z, Dilleman S, Funch-Jensen P, Hedenbro J, Ahmed AR: Clinical indications, utilization, and funding of bariatric surgery in Europe. Obes surg. 2015; 25: 1408–1416. https://doi.org/10.1007/s11695-014-1537-y PMID: 25528567

24. van de Laar AD: The %EBMIL/%EWL Double Booby-Trap. A Comment on Studies that Compare the Effect of Bariatric Surgery Between Heavier and Lighter Patients. Obes Surg. 2016; 26: 612–613. https://doi.org/10.1007/s11695-015-1967-1 PMID: 26620215

25. Alligier M, Meugnier E, Debard C, Lambert-Porcheron S, Chansaume E, Sothier M, et al: Subcutaneous adipose tissue remodeling during the initial phase of weight gain induced by overfeeding in humans. J Clin Endocrinol Metab. 2012; 97: E183–192. https://doi.org/10.1210/jc.2011-2314 PMID: 22162470

26. Pasarica M, Sereda OR, Redman LM, Albarado DC, Hymel DT, Roan LE, Rood JC, Burk DH, Smith SR: Reduced adipose tissue oxygenation in human obesity: evidence for rarefaction, macrophage chemotaxis, and inflammation without an angiogenic response. Diabetes. 2009; 58: 718–725. https://doi.org/10.2337/db08-1098 PMID: 19074987

27. Rausch ME, Weisberg S, Vardhana P, Tortoriello DV: Obesity in C57BL/6J mice is characterized by adipose tissue hypoxia and cytotoxic T-cell infiltration. Int J Obes. 2008; 32: 451–463. https://doi.org/10.1038/sj.io.0803744 PMID: 17895881

28. Ye J, Gao Z, Yin J, He Q: Hypoxia is a potential risk factor for chronic inflammation and adiponectin reduction in adipose tissue of ob/ob and dietary obese mice. Am J Physiol Endocrinol Metab. 2007; 293: E1118–1128. https://doi.org/10.1152/ajpendo.00435.2007 PMID: 17664685

29. Sun K, Tordjman J, Clement K, Scherer PE: Fibrosis and adipose tissue dysfunction. Cell metabolism. 2013; 18: 470–77. https://doi.org/10.1016/j.cmet.2013.06.016 PMID: 23954640

30. Divoux A, Tordjman J, Lacasa D, Veyrie N, Hugol D, Aissat A, et al: Fibrosis in human adipose tissue: composition, distribution, and link with lipid metabolism and fat mass loss. Diabetes. 2010; 59: 2817–2825. https://doi.org/10.2337/db10-0585 PMID: 20713683

31. Bel Lassen P, Charlotte F, Liu Y, Bedossa P, Le Naour G, Tordjman J, et al: The FAT Score, a Fibrosis Score of Adipose Tissue: Predicting Weight-Loss Outcome After Gastric Bypass. Journ Clin Endocrinol Metab. 2017; 102: 2443–2453. https://doi.org/10.1210/jc.2017-00138 PMID: 28419237

32. Lemoine AY, Ledoux S, Queguiner I, Calderari S, Mechler C, Msika S, et al: Link between adipose tissue angiogenesis and fat accumulation in severely obese subjects. Journ Clin Endocrinol Metab. 2012; 97: E775–780. https://doi.org/10.1210/jc.2011-2649 PMID: 22419723

33. Ngo DT, Farb MG, Kikuchi R, Karki S, Tiwari S, Bigornia SJ, et al: Antiangiogenic actions of vascular endothelial growth factor-A165b, an inhibitory isoform of vascular endothelial growth factor-A, in human obesity. Circulation. 2014; 130: 1072–1080. https://doi.org/10.1161/CIRCULATIONAHA.113.008171 PMID: 25116954

34. Livingstone KM, Celis-Morales C, Papadonatou S, Erar B, Florez JC, Jablonski KA, et al: FTO genotype and weight loss: systematic review and meta-analysis of 9563 individual participant data from eight randomised controlled trials. BMJ. 2016; 354:i4707. https://doi.org/10.1136/bmj.i4707 PMID: 27650503

35. Madsbad S, Dirksen C, Holst JJ: Mechanisms of changes in glucose metabolism and bodyweight after bariatric surgery. Lancet Diabetes Endocrinol. 2014; 2: 152–164. https://doi.org/10.1016/S2223-8587(13)70218-3 PMID: 24622719

36. Nielsen MS, Christensen BJ, Schmidt JB, Taekker L, Holm L, Lunn S, et al: Predictors of weight loss after bariatric surgery-a cross-disciplinary approach combining physiological, social, and psychological measures. Int Journ Obes. 2020; 44: 2291–2302

37. Palleja A, Kashani A, Allin KH, Nielsen T, Zhang C, Li Y, et al: Roux-en-Y gastric bypass surgery of morbidly obese patients induces swift and persistent changes of the individual gut microbiota. Genome medicine. 2016; 8: 67. https://doi.org/10.1186/s13073-016-0312-1 PMID: 27306058